Serina Therapeutics, Inc. (SER) Fair Value 2026

SER · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.1 /10

32 fundamental signals · 2 models active

Value Trap Risk

WARN (41/100)

Quick Summary — As of 2026-08-28, Serina Therapeutics, Inc. (SER) trades at $2.46, versus a $0.32 median fair value across its 2 active models — 87.0% below the current price. QOC: 5.1/10. Value Trap Risk: 41/100 (WARN). 2/13 models active.

Key Facts

Ticker
SER
Price
$2.46
Quality Score
5.1/10
Value Trap Risk
41/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Value Trap score of 41 suggests caution despite apparent undervaluation

Is Serina Therapeutics, Inc. (SER) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Serina Therapeutics, Inc. (SER) appears overvalued as of : the median of 2 independent fair value estimates is $0.32, 87.0% below the current price of $2.46. Estimates range from $0.18 to $0.46. SER scores 5.1/10 on fundamental quality and 41/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. SER’s -87.0% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Serina Therapeutics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give SER?

2 Intrinsic Value Models vs. Current Price ($2.46)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.18 -92.7%
Option-Based · Medium Conviction
 $0.46 -81.2%

All Models Active

All 2 models are displayed above.

What Is Serina Therapeutics, Inc. (SER) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Serina Therapeutics, Inc.'s intrinsic value is estimated at $0.32. Trading at its current price of $2.46, the valuation engine raises significant caution: 2 of 2 models flag downside risk, projecting a median implied return of -87.0%.

What Do the Models Say About SER?

2 of 13 models are currently active for SER. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for SER is $0.32 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does SER Rank in Biotechnology?

Among 625 Biotechnology stocks, SER ranks #297 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotech businesses. For Serina Therapeutics, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is SER a Value Trap?

CirclFi's Value Trap algorithm assigns SER a score of 41/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Serina Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Serina Therapeutics, Inc. earns a quality score of 5.1/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

Models cluster within a tight range (+11.4% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SER valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SER's 2 active models, average confidence is 43%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Serina Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

JUNSJupiter Neurosciences, Inc.QOC 5.1SLSSELLAS Life Sciences Group, Inc.QOC 5.1CYDYCytoDyn Inc.QOC 5.1CVKDCadrenal Therapeutics, Inc.QOC 5.1IMNMImmunome, Inc.QOC 5.1FULCFulcrum Therapeutics, Inc.QOC 5.1NRXPNRx Pharmaceuticals, Inc.QOC 4.5TLSATiziana Life Sciences LtdQOC 2.5TSHATaysha Gene Therapies, Inc.QOC 6.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: JUNS · SLS · CYDY · CVKD · IMNM · FULC · NRXP · TLSA · TSHA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to SER?

6 companies across all industries closest to SER’s Quality of Company score of 5.1/10.

OMEXOdyssey Marine Exploration, Inc.QOC 5.1AECAnfield Energy Inc.QOC 5.1BRLLBarrel Energy, Inc.QOC 5.1RPTRithm Property Trust Inc.QOC 5.1ARECAmerican Resources CorporationQOC 5.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: OMEX · AEC · BRLL · RPT · AREC · NVDA

Where Does SER Sit in CirclFi's Biotechnology Rankings?

SER is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Serina Therapeutics, Inc.’s Valuation?

What is Serina Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi puts Serina Therapeutics, Inc. (SER)'s intrinsic value at $0.32 — the median of 2 independent model estimates as of 2026-08-28, ranging from $0.18 to $0.46. The Quality of Company score is 5.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SER overvalued or undervalued right now?

At $2.46, 0 of 2 active models suggest SER may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $0.32, 87.0% below the current price of $2.46 — a consensus view that SER is overvalued. The assessment depends on which methodology best fits Serina Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.1 mean for SER?

Serina Therapeutics, Inc.'s QOC of 5.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SER?

CirclFi analyzes SER with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is SER a value trap in 2026?

Serina Therapeutics, Inc.'s Value Trap score is 41/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Serina Therapeutics, Inc. (SER) has a median fair value of $0.32 — 87.0% below the current price of $2.46 — as of 2026-08-28.” Source: circlfi.com/stock/SER/ · Methodology
Primary sources for this SER valuation
  • Financial statements: Serina Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001708599) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SER as of ; valuations recomputed .